VIACYTE
ViaCyte is a preclinical therapeutic company specializing in regenerative medicine therapies for diabetes. Their therapy is based on the differentiation of stem cells into pancreatic beta-cell precursors, with subcutaneous implantation in an encapsulation device. Data in their publications demonstrate that these cells can produce therapeutically relevant levels of insulin in response to blood glucose, and sustain diabetic animals. Their goal is a product which can free both Type 1 and Type 2 patients with diabetes from insulin dependence on a long-term basis, while reducing or eliminating hypoglycemic, microvasculature, and weight-related cardiovascular complications.
VIACYTE
Industry:
Biotechnology Diabetes Health Care Medical Therapeutics
Founded:
1999-01-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.viacyte.com
Total Employee:
101+
Status:
Closed
Email Addresses:
[email protected]
Total Funding:
235.55 M USD
Technology used in webpage:
Domain Not Resolving SPF Amazon HSTS IPv6 Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS GoDaddy DNS IIS
Similar Organizations
Afya
Afya is a medical education company that helps doctors acquire knowledge throughout their medical careers.
Allm
Allm is a medical ICT company develops innovative mHealth solutions transforming the way healthcare providers collaborate.
Avita Medical
Avita is a medical company that specializes in regenerative medicine, chronic wounds, and plastic surgery.
BrainStorm Cell Therapeutics
Brainstorm is a developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative disorders.
McLaren Racing
One of the most successful teams in Grand Prix racing, creating some of the most iconic cars in the sport's history.
Medicom
Medicom professional customers and distributors we have designed this website.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Tasso
Tasso is a Medical innovation company changing the way diagnostics are delivered
Wellness Forever Medicare
Mumbai-based retail pharmacy chain Wellness Forever Medicare Pvt Ltd
Wright Medical Group
Wright Medical Group is an international medical device company specializing in extremities and biologics.
Current Advisors List
Current Employees Featured
Founder
Investors List
Artis Ventures (AV)
Artis Ventures (AV) investment in Series D - ViaCyte
Adage Capital Management
Adage Capital Management investment in Series D - ViaCyte
Asymmetry Ventures
Asymmetry Ventures investment in Series D - ViaCyte
Invus
Invus investment in Series D - ViaCyte
Bain Capital Life Sciences
Bain Capital Life Sciences investment in Series D - ViaCyte
Sanderling Ventures
Sanderling Ventures investment in Series D - ViaCyte
RA Capital Management
RA Capital Management investment in Series D - ViaCyte
TPG Capital Asia
TPG Capital Asia investment in Series D - ViaCyte
Bain Capital Life Sciences
Bain Capital Life Sciences investment in Series D - ViaCyte
TPG
TPG investment in Series D - ViaCyte
Key Employee Changes
| Date | New article |
|---|---|
| 2021-09-13 | ViaCyte Appoints Stem Cell Therapy Expert Dr. Timothy Kieffer as Chief Scientific Officer |
Official Site Inspections
http://www.viacyte.com Semrush global rank: 10 M Semrush visits lastest month: 283
- Host name: a4ec4c6ea1c92e2e6.awsglobalaccelerator.com
- IP address: 15.197.142.173
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "ViaCyte"
Vertex to Acquire ViaCyte, With the Goal of Accelerating its ...
Jul 11, 2022 · - ViaCyte brings tools, technologies and assets with potential to accelerate development of VX-880, Vertex’s fully differentiated, insulin-producing, stem cell derived islets …See details»
ViaCyte - Crunchbase Company Profile & Funding
ViaCyte is a preclinical therapeutic company specializing in regenerative medicine therapies for diabetes. Their therapy is based on the differentiation of stem cells into pancreatic beta-cell precursors, with subcutaneous implantation in an …See details»
ViaCyte Company Profile 2024: Valuation, Investors, …
Developer of novel cell replacement therapies and regenerative medicine intended to address critical human diseases and disorders.See details»
ViaCyte and CRISPR Introduce New Stem Cell Therapy …
In a collaboration between ViaCyte and CRISPR Therapeutics, a new clinical trial is investigating a stem cell therapy that may eventually help millions with type 1 diabetes. Researchers have long sought a cell-based “cure” for type 1 …See details»
ViaCyte Reports Compelling Preliminary Clinical Data …
Jun 25, 2021 · ViaCyte is a privately held clinical-stage regenerative medicine company developing novel cell replacement therapies based on two major technological advances: cell replacement...See details»
ViaCyte Company Profile - Office Locations, Competitors ... - Craft
ViaCyte is a regenerative medicine company focused on developing a transformative cell replacement therapy to free people with insulin-requiring diabetes from painful and frequent …See details»
ViaCyte Overview: T1D Practical Cure Progress - The …
Feb 9, 2022 · One of the most talked-about companies pursuing a T1D Practical Cure is ViaCyte, the San Diego company that hopes to use stem cells to provide a functional cure for T1D. The company has raised over $100 million, mostly …See details»
Vertex buys diabetes cell therapy rival ViaCyte for $320m
2 days ago · Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX …See details»
ViaCyte's Stem Cell-Derived Treatment for Type 1 …
Dec 2, 2021 · ViaCyte is advancing PEC-Direct and its portfolio of stem cell-derived therapies with the goal of enabling patients with diabetes to regulate their blood glucose levels, improve health...See details»
ViaCyte - VentureRadar
Website: http://viacyte.com Develops regenerative cell replacement therapies for long-term diabetes treatment, aiming to control glucose levels and reduce hypoglycemia and related …See details»
ViaCyte - Funding, Financials, Valuation & Investors - Crunchbase
Sep 11, 2020 · ViaCyte is a preclinical therapeutic company specializing in regenerative medicine therapies for diabetes.See details»
ViaCyte Appoints Michael Yang President and CEO and Provides …
Jan 27, 2021 · ViaCyte is a privately held regenerative medicine company developing novel cell replacement therapies based on two major technological advances: cell replacement therapies …See details»
Vertex to Acquire ViaCyte for $320M, Growing Diabetes Cell …
Jul 11, 2022 · Vertex Pharmaceuticals said today it has agreed to acquire ViaCyte for $320 million cash, in a deal that bolsters the buyer’s diabetes pipeline with ViaCyte’s triple-pronged attack …See details»
Johnson & Johnson, ViaCyte testing possible diabetes cure
Feb 4, 2016 · Johnson & Johnson, continuing its long quest for a Type 1 diabetes cure, is joining forces with biotech company ViaCyte to speed development of the first stem cell treatment that …See details»
ViaCyte Announces Closing of $45 Million Financing to Advance …
Jun 9, 2021 · ViaCyte is a privately held regenerative medicine company developing novel cell replacement therapies based on two major technological advances: cell replacement therapies …See details»
Vertex to Acquire ViaCyte, With the Goal of Accelerating its ...
Jul 11, 2022 · ViaCyte is a private cellular therapy company with a clinical-stage stem cell platform that delivers therapeutic proteins to restore health in people.See details»
ViaCyte Announces Closing of $45 Million Financing to Advance …
Jun 9, 2021 · ViaCyte is a privately held regenerative medicine company developing novel cell replacement therapies based on two major technological advances: cell replacement therapies …See details»
ViaCyte Announces $27 Million Financing to Advance Next …
May 26, 2020 · ViaCyte is a privately held regenerative medicine company developing novel cell replacement therapies as potential long-term diabetes treatments to achieve glucose control …See details»
After years of failure, ViaCyte shows off first proof-of-concept for ...
Jun 25, 2021 · Seven years after they first tried it, ViaCyte finally has data showing that their stem cell treatment for diabetes — a potential cure — can work in a patient. The data are ...See details»
ViaCyte and Gore Expand Collaboration to Develop Novel …
Mar 2, 2021 · ViaCyte is a privately held regenerative medicine company developing novel cell replacement therapies based on two major technological advances: cell replacement therapies …See details»